A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
Completed · Phase 1
Conditions studied: Attention-deficit Hyperactivity Disorder
In brief
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
Key facts
- Study ID
- NCT04786730
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- People needed
- 50
- Starts
- 2021-03-09
- Expected to finish
- 2023-04-26
- Last updated by the study team
- 2023-07-13
Who can join
Age: 4 and older, up to 12. Sex: any. Healthy volunteers: not accepted.
Where it is running
- For additional information regarding sites, contact 844-687-8522 — Little Rock, Arkansas, United States
- For additional information regarding sites, contact 844-687-8522 — Decatur, Georgia, United States
- For additional information regarding sites, contact 844-687-8522 — Las Vegas, Nevada, United States
- For additional information regarding sites, contact 844-687-8522 — Oklahoma City, Oklahoma, United States
- For additional information regarding sites, contact 844-687-8522 — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.